Cohance Lifesciences Ltd Financial Statement
*All values are in Rs. Cr
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|
| Revenue | 496.68 | 776.76 | 299.77 |
| Operating Expense | 387.48 | 561.58 | 171.05 |
| Net Profit | 52.57 | 122.77 | 83.67 |
| Net Profit Margin | 10.58 | 15.81 | 27.91 |
| Earning Per Share | 1.38 | 3.22 | 3.29 |
| EBIDTA | 108.88 | 203.09 | 142.96 |
| Effective Tax Rate | 16.62 | 14.29 | 32.47 |
| Particulars | Jun 2025 |
|---|---|
| Revenue | 496.68 |
| Operating Expense | 387.48 |
| Net Profit | 52.57 |
| Net Profit Margin | 10.58 |
| Earning Per Share | 1.38 |
| EBIDTA | 108.88 |
| Effective Tax Rate | 16.62 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Total Revenue Annual | 1,093.51 | 1,051.35 | 1,330.08 |
| Operating Expenses Annual | 730.94 | 645.49 | 739.39 |
| Operating Profit Annual | 416.55 | 462.47 | 635.24 |
| Interest Annual | 8 | 7.45 | 12.75 |
| Depreciation | 50.06 | 51.03 | 42.70 |
| Net Profit Annual | 271.71 | 296.47 | 432.60 |
| Tax Annual | 79.64 | 103.95 | 146.79 |
| Particulars | Mar 2025 |
|---|---|
| Total Revenue Annual | 1,093.51 |
| Operating Expenses Annual | 730.94 |
| Operating Profit Annual | 416.55 |
| Interest Annual | 8 |
| Depreciation | 50.06 |
| Net Profit Annual | 271.71 |
| Tax Annual | 79.64 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Cash Flow at the Beginning | 18.46 | 44.65 | 30.21 |
| Cash Flow from Operations | 301.03 | 376.20 | 492.82 |
| Cash Flow from Investing | -320.94 | -362.40 | -236.86 |
| Cash Flow from Financing | 20.81 | -39.99 | -243.14 |
| Cash Flow at the End | 19.36 | 18.46 | 43.02 |
| Particulars | Mar 2025 |
|---|---|
| Cash Flow at the Beginning | 18.46 |
| Cash Flow from Operations | 301.03 |
| Cash Flow from Investing | -320.94 |
| Cash Flow from Financing | 20.81 |
| Cash Flow at the End | 19.36 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| PBDIT Margin (%) | 38.09 | 43.99 | 47.76 |
| PBIT Margin (%) | 32.86 | 38.79 | 44.52 |
| PBT Margin (%) | 28.75 | 33.58 | 41.03 |
| Net PROFIT Margin (%) | 24.85 | 28.20 | 32.52 |
| Return On Networth / Equity (%) | 12.51 | 15.70 | 26.46 |
| Return On Networth /Employed (%) | 15.94 | 20.80 | 34.28 |
| Return On Assets (%) | 12.18 | 15.23 | 25.04 |
| Total Debt / Equity (X) | 0.04 | 0.04 | 0.05 |
| Asset Turnover Ratio (%) | 0.49 | 0.54 | 0.77 |
| Particulars | Mar 2025 |
|---|---|
| PBDIT Margin (%) | 38.09 |
| PBIT Margin (%) | 32.86 |
| PBT Margin (%) | 28.75 |
| Net PROFIT Margin (%) | 24.85 |
| Return On Networth / Equity (%) | 12.51 |
| Return On Networth /Employed (%) | 15.94 |
| Return On Assets (%) | 12.18 |
| Total Debt / Equity (X) | 0.04 |
| Asset Turnover Ratio (%) | 0.49 |
*All values are in Rs. Cr
Standalone
Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| Fixed Assets Annual | 685.57 | 669.73 | 512.03 |
| Total Current Assets Annual | 708.76 | 1,224.23 | 955.12 |
| Non Current Assets Annual | 1,879.05 | 990.65 | 1,003.21 |
| Total Shareholders Funds Annual | 2,315.55 | 2,028.35 | 1,749.38 |
| Total Assets Annual | 2,587.81 | 2,214.88 | 1,958.33 |
| Particulars | Mar 2025 |
|---|---|
| Fixed Assets Annual | 685.57 |
| Total Current Assets Annual | 708.76 |
| Non Current Assets Annual | 1,879.05 |
| Total Shareholders Funds Annual | 2,315.55 |
| Total Assets Annual | 2,587.81 |
EPS (INR)
Expected
1.28
Reported
1.28
Surprise
0.00%
Mar 2025
EPS beaten by 0.00%
Dec 2024
EPS beaten by -33.19%
Sep 2024
EPS beaten by 0.00%
